Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Predialysis chronic kidney disease with GFR \< 90 mL/min/1.73m2
PTH above the upper limit of normal
serum calcium and phosphate below the upper limit of normal
You may not be if
changes in GFR\>15% during the past 3 months
receive elemental calcium\>500 mg/day
currently taking active vitamin D, oral calcium with elemental calcium\>500 mg/day or bisphosphonate
